Hydroxystaurosporine (UCN-01) is a selective protein kinase C inhibitor in clinical trial for
cancer treatment. In this study, we found that nanomolar concentrations of camptothecin …

DNA-damaging agents arrest cell cycle progression at either G1 or G2. A variety of agents
such as caffeine have been shown to abrogate the DNA damage-dependent G2 checkpoint …

We have previously reported that UCN‐01 (7‐hydroxystaurosporine), a protein kinase
inhibitor that is under clinical trials as an anti‐cancer agent in the USA and Japan, enhanced …

Derivatives of camptothecins, topoisomerase I inhibitors and 7‐hydroxystaurosporine (UCN‐
01), a protein kinase C (PKC) inhibitor and cell cycle checkpoint abrogator, are promising …

7-hydroxystaurosporine (UCN-01) is a more selective protein kinase C inhibitor than
staurosporine. UCN-01 exhibits antitumor activity in experimental tumor models and is …

Human myeloid leukemia ML-1 cells responded to cytostatic concentrations of fludarabine
nucleoside (F-ara-A) by instituting an arrest in S-phase that involved the inhibition of cyclin …

Camptothecin (CPT) derivatives are topoisomerase I (top1) inhibitors recently introduced as
clinical agents. To explore the role of p53 in CPT-induced cytotoxicity, we examined CPT …

A variety of agents, such as caffeine, have been shown to abrogate the DNA damage-
dependent G2 checkpoint and enhance cytotoxicity. However, these agents are too toxic for …

In response to DNA damage, cells arrest progression through the cell cycle at either G1, S,
or G2. We have reported that UCN-01 (7-hydroxystaurosporine) abrogates DNA damage …

Previous cell line comparisons indicated that neither S-phase fraction nor topoisomerase I
(top1) levels are sufficient to predict camptothecin (CPT) cytotoxicity (F. Goldwasser et al …